Fisher Asset Management LLC Cuts Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Fisher Asset Management LLC reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,449 shares of the medical equipment provider’s stock after selling 3,348 shares during the quarter. Fisher Asset Management LLC owned approximately 0.22% of Lantheus worth $16,841,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in LNTH. GAMMA Investing LLC lifted its position in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares during the last quarter. Signaturefd LLC lifted its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the last quarter. Nkcfo LLC purchased a new position in Lantheus in the second quarter worth $47,000. UMB Bank n.a. increased its position in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus during the 3rd quarter valued at $51,000. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. Truist Financial restated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities decreased their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Price Performance

NASDAQ:LNTH opened at $90.27 on Thursday. The firm has a market capitalization of $6.28 billion, a P/E ratio of 15.02 and a beta of 0.51. The company’s fifty day moving average price is $102.48 and its 200-day moving average price is $97.13. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.